0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Review |

Nonalcoholic Fatty Liver Disease A Challenge for Pediatricians

Valerio Nobili, MD1; Naim Alkhouri, MD2; Anna Alisi, PhD1; Claudia Della Corte, MD1; Emer Fitzpatrick, MD3; Massimiliano Raponi, MD1; Anil Dhawan, MD3
[+] Author Affiliations
1Hepato-Metabolic Disease Unit, Bambino Gesù Children’s Hospital, Italian Scientific Institute for Research and Care, Rome, Italy
2Department of Pediatric Gastroenterology and Hepatology, Cleveland Clinic Children’s Medical Center, Cleveland, Ohio
3Paediatric Liver, Gastrointestinal, and Nutrition Centre, King’s College London School of Medicine, King’s College Hospital, London, England
JAMA Pediatr. 2015;169(2):170-176. doi:10.1001/jamapediatrics.2014.2702.
Text Size: A A A
Published online

Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and is considered the most common form of chronic liver disease in children. Several factors contribute to NAFLD development, including race/ethnicity, genetic factors, environmental exposures, and alterations in the gut microbiome. The histologic spectrum of NAFLD ranges from simple steatosis to the more aggressive nonalcoholic steatohepatitis (NASH). Fibrosis and eventually cirrhosis can develop from NAFLD during childhood. Diagnosing advanced disease is challenging and may require a liver biopsy, highlighting the urgent need for reliable, noninvasive markers of disease severity. The mainstay of treatment for NAFLD remains lifestyle modifications and weight loss. Probiotics and ω-3 fatty acids may ameliorate disease progression. Recent data have suggested that vitamin E may be considered as a NASH-specific therapy in children, and there are several ongoing human studies evaluating different therapeutic targets for NAFLD. We provide an up-to-date review of the risk factors, diagnosis, and treatment to manage this common disease in children.

Figures in this Article

Figures

Place holder to copy figure label and caption
Figure 1.
Risk Factors Associated With the Pathogenesis of Nonalcoholic Fatty Liver Disease (NAFLD)

IL-6 indicates interleukin 6; INSIG, insulin-induced gene; KLF-6, Krüppel-like factor; PNPLA3, patatinlike phospholipase domain–coding protein; PUFA, polyunsaturated fatty acid; SNPs, single-nucleotide polymorphisms; and TNF, tumor necrosis factor.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Proposed Mechanism for the Beneficial Effects of Docosahexaenoic Acid (DHA)

During the development of nonalcoholic fatty liver disease (NAFLD), G protein–coupled receptor (GPR120) expressed in liver resident cells may activate the transcription of proinflammatory cytokines, including tumor necrosis factor (TNF) and interleukins (IL-6 and IL-1β), via phosphorylated nuclear factor–κB (pNF-κB). Administration of DHA may inhibit this process.

Graphic Jump Location

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

2,897 Views
15 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();